Form 4: Alnylam Pharmaceuticals Director Dennis A. Ausiello Reports Stock and Option Transactions

Director Dennis A. Ausiello reports acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Summary

• On May 8, 2025, Dennis A. Ausiello, a director of Alnylam Pharmaceuticals, reported the acquisition of 775 restricted stock units (RSUs) and 1,558 stock options.
• The RSUs were granted under the Amended and Restated 2018 Stock Incentive Plan and each RSU represents a contingent right to receive one share of common stock.
• The stock options have an exercise price of $258.35 and expire on May 8, 2035.
• Both the RSUs and stock options vest in full upon the earlier of the first anniversary of the grant date (May 8, 2026) or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• Ausiello also indirectly owns 3,500 shares of Alnylam common stock through a trust where his spouse is the trustee.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of RSUs and stock options by a director may signal confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the RSUs and stock options suggests a long-term commitment from the director.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment if interpreted as a sign of confidence from a company director.

Key Dates

Keywords

Alnylam Pharmaceuticals, Director, Stock Options, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership, Insider Trading